title: [Diagnosis and management of adverse events occuring during BCG therapy for non-muscle invasive bladder cancer (NMIBC): review of the Cancer Committee of the French Association of Urology].
abstract: BACKGROUND
  Intravesical BCG immuno-therapy with maintenance therapy is considered as the standard treatment for non-muscle invasive bladder cancer with high risk of recurrence and progression. In practice, adverse events (AEs) of BCG therapy could restrict its prescription by urologists. The aim of this article was to present a review of these AEs and of their management.
  
  
  METHODS
  A bibliographic research in French and English using Medline(®) and Embase(®) with the keywords "BCG", "bladder", "complication", "toxicity", "adverse reaction", "prevention" and "treatment" was performed.
  
  
  RESULTS
  The main mechanism of AEs of BCG are infectious (cystitis, fever), immuno-allergic (granulomatous prostatitis, epididymo-orchitis, and granulomatous reactions) and auto-immune (arthralgies, rash). Management of AEs is based on their pathophysiological mechanisms. Classifications of BCG therapy AEs based on clinical features allow to adapt their treatments.
  
  
  CONCLUSIONS
  The combination of antibiotics directed against BCG, steroid or non-steroidal anti-inflammatory medication and symptomatic treatment is currently the triad on which is set up the appropriate treatment of severe AEs. Reductions of BCG doses and ofloxacin medication after instillation decrease the frequency and severity of minor and moderate AEs. Severe or more than 7 days long infectious AEs, immuno-allergic AEs or auto-immune during more than 7 days impose cessation of BCG immuno-therapy.
authors.affiliation: Service d'urologie, université de Versailles-Saint-Quentin-en-Yvelines, hôpital Foch, Suresnes, France. y.neuzillet@hopital-foch.org
authors.forename: Y
authors.initials: Y
authors.lastname: Neuzillet
authors.forename: M
authors.initials: M
authors.lastname: Rouprêt
authors.forename: H
authors.initials: H
authors.lastname: Wallerand
authors.forename: G
authors.initials: G
authors.lastname: Pignot
authors.forename: S
authors.initials: S
authors.lastname: Larré
authors.forename: J
authors.initials: J
authors.lastname: Irani
authors.forename: J-L
authors.initials: JL
authors.lastname: Davin
authors.forename: J-L
authors.initials: JL
authors.lastname: Moreau
authors.forename: M
authors.initials: M
authors.lastname: Soulié
authors.forename: C
authors.initials: C
authors.lastname: Pfister
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000283:Administration, Intravesical; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D018771:Arthralgia / Q000175:diagnosis / Q000276:immunology; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D003556:Cystitis / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D004334:Drug Administration Schedule; D004823:Epididymitis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D005334:Fever / Q000276:immunology; D005602:France; D006099:Granuloma / Q000175:diagnosis / Q000276:immunology; D006801:Humans; D008297:Male; D009361:Neoplasm Invasiveness; D015242:Ofloxacin / Q000627:therapeutic use*; D009920:Orchitis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D017410:Practice Guidelines as Topic; D011472:Prostatitis / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D012955:Societies, Medical; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D014572:Urology
chemical_list: D000276:Adjuvants, Immunologic; D000892:Anti-Infective Agents, Urinary; D001500:BCG Vaccine; D015242:Ofloxacin